EcoDrugPlus

Epidermal Growth Factor Receptor

Ensembl ID : ENSMLEG00000035929
Gene Symbol: EGFR
4 Cross references
285 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Epoxide Hydrolase 2

Ensembl ID : ENSMLEG00000029411
Gene Symbol: EPHX2
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSMLEG00000032400
Gene Symbol: ERBB2
4 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSMLEG00000031798
Gene Symbol: ERBB3
4 Cross references
282 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSMLEG00000024990
Gene Symbol: ERBB4
4 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Receptor 1

Ensembl ID : ENSMLEG00000040148
Gene Symbol: ESR1
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Receptor 2

Ensembl ID : ENSMLEG00000036116
Gene Symbol: ESR2
4 Cross references
273 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Related Receptor Gamma

Ensembl ID : ENSMLEG00000040849
Gene Symbol: ESRRG
4 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Exportin 1

Ensembl ID : ENSMLEG00000032004
Gene Symbol: XPO1
4 Cross references
304 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyl Diphosphate Synthase

Ensembl ID : ENSMLEG00000000066
Gene Symbol: FDPS
4 Cross references
226 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSMLEG00000009881
Gene Symbol: FDFT1
4 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSMLEG00000021203
Gene Symbol: FNTA
4 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).